HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
Abstract: Thymidine-analogue mutations (TAMs)-1 [T215FY (46.53%), M41 L (22.77%), L210 W (8.91%)], with cross-resistance to AZT and TDF, were higher compared to TAMs-2 [D67N (21.78%), K70R (19.80%), K219QE (18.81%)].
Result: Of note, TAMs-1 were predominant (T215F/Y: 46.5%; M41 L: 22.8%; L210 W: 8.9%) and associated with higher levels of resistance to both AZT and TDF; as compared to TAMs-2 that had relatively lower prevalence (D67N: 21.8%; K70R: 19.8%; K219Q/E: 18.8%) and were associated preferentially with AZT/D4T-resistance.
Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
Discussion: The primary resistance mutations to AZT are T215F/Y and/or K70R.
Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
PMID: 30989237
2019
The Journal of antimicrobial chemotherapy
Abstract: The most prevalent RAMs were K103N (40.7%), M184V (28.8%), D67N (15.3%) and T215I/F/Y (15.3%).
Result: The most prevalent RT RAMs were as follows: K103N (n = 24, 40.7%), M184V (n = 17, 28.8%), D67N (n = 9, 15.3%), T215I/F/Y (n = 9, 15.3%) and M41L (n = 7, 11.9%) (Figure 1).
HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.
PMID: 31117863
2019
Journal of the International Association of Providers of AIDS Care
Table: T215Y
Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam.
Discussion: TAMs occur in different patterns: type 1 includes M41L, L210W and T215Y (14%, 11.6% and 4.7% prevalence, respectively, in our study), and type 2 includes K70R, D67N T215F and K219Q/E (37.2%, 27.9%, 27.9% and 14% prevalence, respectively, in our study).
Discussion: The accumulation of other mutations observed included TAMs (including M41L, L210W, T215Y, K70R, D67N, T215F and K219Q), resulting in increased resistance to AZT, TDF,
Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.
Analysis of generalized semiparametric mixed varying-coefficients models for longitudinal data.
PMID: 31827312
2019
The Canadian journal of statistics
Introduction: ACTG 244 enrolled HIV-infected patients receiving zidovudine (ZDV) monotherapy, and monitored them every eight weeks for occurrence of the 215 (T215Y/F) ZDV resistance mutation.
Introduction: ACTG 244 enrolled HIV-infected patients taking zidovudine (ZDV) monotherapy and monitored their HIV in plasma every eight weeks for presence of the T215Y/F ZDV resistance mutation.
Introduction: In conclusion, switching to the combination therapies based on the T215Y mutation has positive benefits as compared to continuing with ZDV monotherapy ZDV even after drug-resistant virus was detected.
Introduction: Let S1 be the time between the dates of study entry and the first randomization triggered by occurrence of the T215Y/F
Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Result: Eleven (25%, 11/44) of the RTRM were thymidine analogue mutations (T215FY [2.5%, 6/239], K70R [1.7%, 4/239] and 0.8% (2/239) each of D67N, L210W, M41L, and K219Q/E (Fig 2).
Result: The mutational pattern, D67N-M41L-M184V-L210W-T215F/Y was
Table: T215F/Y
Discussion: The second prevalent resistance-associated mutations were T215Y/F and Y181C in the NRTI and NNRTI respectively.
Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.
Result: The sequence originating from the UK had a similar mutation pattern with additional SDRMs (PI: M46L, V82A and NRTI: T215Y).
Discussion: Phylogenetic inference indicated a transmission link with one UK sequence with a similar mutation pattern, PI: V32I, M46L, I47A, V82A + NRTI: T215Y + NNRTI: L100I, K103N.
Discussion: These variants develop from strains containing T215Y/F mutations, primarily selected under
High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Method: Primary NRTI-R substitutions were M41L, K65R/E/N, D67N, T69 insertions, K70E/R, L74V/I, Y115F, Q151M, M184V/I, L210W, T215Y/F and K219E/Q/N/R in RT.
Result: Pre-existing NRTI-R substitutions were observed in 16% (89/543) of BIC/FTC/TAF-treated participants; the most frequently detected substitutions were M184V/I in 10% (54/543) and thymidine analogue mutations (TAMs; M41L
HIV mutation literature information.
PMID: 
2019
BMC infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT